NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

This is a Phase III open-label, 3-arm, parallel, randomized, controlled trial. The allocation ratio 1:1:1 and outcome assessment are blind to group allocation. Patients will be randomized from 3 arms. Patients will receive VRD extended + ASCT plus ERI or Isatuximab-VRD + ASCT or Isatuximab-VID + ASCT.

Trial Details

NCT ID
NCT05558319
Phase
PHASE3
Sponsor
PETHEMA Foundation
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Bortezomib
  • Isatuximab
  • Iberdomide
  • Lenalidomide
  • Dexamethasone
Locations (sample)
  • Alcalá de Henares, Madrid, Spain|40.48205,-3.35996
  • Madrid, Spain|40.4165,-3.70256
  • Pamplona, Navarre, Spain|42.81687,-1.64323
  • Albacete, Spain|38.99424,-1.85643
  • Badalona, Spain|41.45004,2.24741

Key Eligibility Criteria

  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  • Patient must be able to understand the study procedures.
  • Patient has given voluntary written informed consent before performance of any studyrelated procedure non part of normal medical care, with the und…
  • Newly diagnosed multiple myeloma patient who requires start active treatment according to the 2014 IMWG criteria, namely clonal bone marrow plasma …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →